Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$926 Mln
Revenue (TTM)
$151 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
10.6
Industry P/E
--
EV/EBITDA
-1.2
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$--
EPS
$-0.6
Face value
--
Shares outstanding
97,466,704
CFO
$-469.90 Mln
EBITDA
$-323.51 Mln
Net Profit
$-337.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Poseida Therapeutics (PSTX)
| -1.0 | 1.5 | 257.1 | 199.7 | 14.1 | -- | -- |
|
BSE Sensex*
| 4.5 | 0.2 | 4.1 | 1.3 | 15.0 | 17.2 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Poseida Therapeutics (PSTX)
| 183.3 | -36.6 | -22.2 | -37.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase... I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. As of January 7, 2025, Poseida Therapeutics, Inc. operates as a subsidiary of Roche Holdings, Inc. Read more
Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Poseida Therapeutics Inc (PSTX) stood at $ 372 Mln as on 30-Sep-24
The share price of Poseida Therapeutics Inc (PSTX) is $9.50 (NASDAQ) as of 08-Jan-2025 09:30 EDT. Poseida Therapeutics Inc (PSTX) has given a return of 14.13% in the last 3 years.
Poseida Therapeutics Inc (PSTX) has a market capitalisation of $ 926 Mln as on 08-Jan-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Poseida Therapeutics Inc (PSTX) is 10.62 times as on 08-Jan-2025, a 234% premium to its peers’ median range of 3.18 times.
Since, TTM earnings of Poseida Therapeutics Inc (PSTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Poseida Therapeutics Inc (PSTX) and enter the required number of quantities and click on buy to purchase the shares of Poseida Therapeutics Inc (PSTX).
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. As of January 7, 2025, Poseida Therapeutics, Inc. operates as a subsidiary of Roche Holdings, Inc.
The CEO & director of Mr. Mark J. Gergen J.D.. is Poseida Therapeutics Inc (PSTX), and CFO & Sr. VP is Mr. Mark J. Gergen J.D..
There is no promoter pledging in Poseida Therapeutics Inc (PSTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Poseida Therapeutics Inc. (PSTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-69.15
|
|
Operating margin(%)
|
-34.23
|
|
Net Margin(%)
|
-39.37
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Poseida Therapeutics Inc (PSTX) was $0 Mln.
